Sibrafiban (BioDeep_00001028792)
代谢物信息卡片
Sibrafiban
化学式: C20H28N4O6 (420.2008748)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCOC(=O)COC1CCN(CC1)C(=O)C(C)NC(=O)C2=CC=C(C=C2)C(=NO)N
InChI: InChI=1S/C20H28N4O6/c1-3-29-17(25)12-30-16-8-10-24(11-9-16)20(27)13(2)22-19(26)15-6-4-14(5-7-15)18(21)23-28/h4-7,13,16,28H,3,8-12H2,1-2H3,(H2,21,23)(H,22,26)/t13-/m0/s1
描述信息
D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors
同义名列表
1 个代谢物同义名
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Mukund M Mehrotra, Julie A Heath, Mark S Smyth, Anjali Pandey, Jack W Rose, Joseph M Seroogy, Deborah L Volkots, Lisa Nannizzi-Alaimo, Gary L Park, Joseph L Lambing, Stanley J Hollenbach, Robert M Scarborough. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
Journal of medicinal chemistry.
2004 Apr; 47(8):2037-61. doi:
10.1021/jm030354b. [PMID: 15056002] - L Kristin Newby, Arni Kristinsson, Manjushri V Bhapkar, Philip E Aylward, Alexios P Dimas, Werner W Klein, Darren K McGuire, David J Moliterno, Freek W A Verheugt, W Douglas Weaver, Robert M Califf. Early statin initiation and outcomes in patients with acute coronary syndromes.
JAMA.
2002 Jun; 287(23):3087-95. doi:
10.1001/jama.287.23.3087. [PMID: 12069671] - J D Reimann, N B Modi, W Novotny. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparin.
Journal of clinical pharmacology.
2000 May; 40(5):488-95. doi:
10.1177/00912700022009107. [PMID: 10806602] - B Wittke, H Ensor, J Chung, H Birnböck, B Lausecker, S I Ertel, I J MacKie, S J Machin. Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin.
British journal of clinical pharmacology.
2000 Mar; 49(3):231-9. doi:
10.1046/j.1365-2125.2000.049003231.x. [PMID: 10718778] - NULL. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes.
Lancet (London, England).
2000 Jan; 355(9201):337-45. doi:
10.1016/s0140-6736(99)11179-6. [PMID: 10665552] - U Timm, H Birnböck, R Erdin, G Hopfgartner, R Zumbrunnen. Determination of the oral platelet aggregation inhibitor Sibrafiban in rat, dog, and human plasma utilising HPLC-column switching combined with turbo ion spray single quadrupole mass spectrometry.
Journal of pharmaceutical and biomedical analysis.
1999 Oct; 21(1):151-63. doi:
10.1016/s0731-7085(99)00126-0. [PMID: 10701922] - L K Newby. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee.
American heart journal.
1999 Aug; 138(2 Pt 1):210-8. doi:
10.1016/s0002-8703(99)70104-3. [PMID: 10426831] - N B Modi, W Novotny, J D Reimann, C P Cannon, E Braunwauld. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome.
Journal of clinical pharmacology.
1999 Jul; 39(7):675-84. doi:
10.1177/00912709922008317. [PMID: 10392322] - B Wittke, I J Mackie, S J Machin, U Timm, M Zell, T Goggin. Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers.
British journal of clinical pharmacology.
1999 May; 47(5):521-30. doi:
10.1046/j.1365-2125.1999.00931.x. [PMID: 10336576] - M Dooley, K L Goa. Sibrafiban.
Drugs.
1999 Feb; 57(2):225-30; discussion 231. doi:
10.2165/00003495-199957020-00012. [PMID: 10188763] - N B Modi, Y S Lin, T Reynolds, A Shaheen, B J Christian. Pharmacokinetics and pharmacodynamics of sibrafiban (Ro 48-3657), an orally active IIb/IIIa antagonist, administered alone or in combination with heparin, aspirin, and recombinant tissue-type plasminogen activator in beagles.
Journal of cardiovascular pharmacology.
1998 Sep; 32(3):397-405. doi:
10.1097/00005344-199809000-00010. [PMID: 9733353] - C J Refino, N B Modi, S Bullens, C Pater, M T Lipari, K Robarge, B Blackburn, M Beresini, T Weller, B Steiner, S Bunting. Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form.
Thrombosis and haemostasis.
1998 Jan; 79(1):169-76. doi:
10.1055/s-0037-1614238. [PMID: 9459344] - U Timm, R Zumbrunnen, R Erdin, M Singer, B Steiner. Oral platelet aggregation inhibitor Ro 48-3657: determination of the active metabolite and its prodrug in plasma and urine by high-performance liquid chromatography using automated column switching.
Journal of chromatography. B, Biomedical sciences and applications.
1997 Apr; 691(2):397-407. doi:
10.1016/s0378-4347(96)00477-x. [PMID: 9174277] - M Zell, C Husser, G Hopfgartner. Column-switching high-performance liquid chromatography combined with ionspray tandem mass spectrometry for the simultaneous determination of the platelet inhibitor Ro 44-3888 and its pro-drug and precursor metabolite in plasma.
Journal of mass spectrometry : JMS.
1997 Jan; 32(1):23-32. doi:
10.1002/(sici)1096-9888(199701)32:1<23::aid-jms449>3.0.co;2-p. [PMID: 9008866]